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The safety and management of cancer patients in the current SARS-CoV-2 outbreak is urgent 
and most cancer clinics need to establish a contingency plan. It is well established that cancer 
patients are more susceptible to infections because of the immunosuppressive state caused by 
both anticancer treatments and surgery [1-3]. A recent study from Prof He and colleagues 
shows that the risk of developing severe events in COVID-19 disease is statistically significant 
higher in patients with cancer, with a hazard ratio of 3.56 [4]. A caution in interpreting the data is 
that the patient numbers are of course small, but the results are not unexpected. The authors 
suggest that postponing adjuvant chemotherapy or elective surgery for less aggressive cancers 
should be considered and that the increased risk for personal protection provisions should be 
emphasized for patients with cancer or cancer survivors. Furthermore, more intensive 
surveillance or treatment should be considered for those patients with cancer who are infected 
with SARS-CoV-2 virus. 
 
Currently, the COVID-19 disease situation is particularly pressing in Italy, which is challenging 
for the Aviano Cancer Centre, a National Cancer Institute that attracts patients and relatives 
from all over the country. Tents have been built in front of each hospital entrance, serving as 
triage areas. Nurses and doctors work around the clock, evaluating the personal and medical 
history of each incoming patient, visitor and guest. Dedicated staff in protected areas evaluate 
patients who present with respiratory symptoms or fever. The COVID-19 test is performed in 
suspected cases according to national health system recommendations. Visits to inpatients 
have been limited to one guest per day and forbidden in the hematology division. Outpatients 
are allowed with only one companion and limited to underage or non-self-sufficient patients. 
Patients with a scheduled follow-up visit who report suspected symptoms are encouraged to 
contact their physician to reschedule their visit. For all medical and para-medical staff, 
multidisciplinary boards have been limited to one specialist per board. Morning meetings and 
journal clubs have been suspended, but allowed via teleconference. The library service has 
been closed until further notice, and so has the visitor’s canteen. Medical students’ trainee 
programs have been postponed.  Importantly, the aforementioned restrictions have not affected 
chemotherapy or other programs of systemic treatment or surgery. Follow-up visits were 
suspended for two weeks pending decisions related to the evolution of the epidemic.   
 
However, in addition to the apparent threats the COVID-19 poses, both to single individuals and 
health systems, this epidemic hides subtle menaces, like the distraction effect. It is mandatory, 
especially in a finite resource system to balance the potential benefit of containment measures, 
such as postponing scheduled procedures, with negative health and social costs.  Diverting the 
attention exclusively to the COVID-19 situation and overshadowing the everyday clinical 
practice may have substantial negative implications, especially for cancer patients. Re-
allocating an excessive amount of healthcare personnel, both nurses and doctors, to the 
COVID-19 triage and management may stretch an already fragile system and potentially leave 
uncovered some vital activities, such as treatment administration, surgeries and inpatient 
assistance. It is well established that delayed oncologic surgery may lead to disease 
progressions and result in tumors no longer resectable, leading to worse survival outcomes.  
The same goes for neoadjuvant or adjuvant chemotherapy regimens administered with sub-
optimal timing. It should be emphasized that we are talking about patients potentially cured by 
oncologic treatments. Therefore, any delay of these fundamental procedures, either intentional 
or due to shortage of personnel, should be avoided. The same risk is present for the people who 
have scheduled screening activities (e.g. screening mammography for the early diagnosis of 
breast cancer). People should be advised to maintain their scheduled appointments, if the 
procedure is feasible safely, or at least to promptly reschedule their appointment when the 
epidemic it is expected to slow its pace. For patients with advanced disease, as oncologists we 
know the enormous negative impact from disease progression in terms of both survival time and 
quality of life. The inability to deliver palliative care to patients unable to move from their homes 
and the management of treatment side effects are other significant concerns from a forced 
quarantine [5]. Patients with advanced disease, and no suggestive symptoms of COVID-19, 
should keep receiving planned chemotherapy or radiotherapy treatment, without unnecessary 
delays. Moreover, although postponing follow-up and cancer prevention appointments is a 
strategy to be considered, an excessive accumulation of visits or examinations risks burdening 
the national public health system over the next few months. 
 
At this moment, we cannot tell when the current outbreak will end, as this will happen when the 
number of infected people falls to a critical threshold (the Critical Community Size), which is too 
low to sustain viral spread. In practice, this is going to be a result of the interplay of containment, 
emerging immunity, viral evolution and weather (Figure 1). However, looking back at past 
outbreaks and pandemics, complete eradication of a pathogen after its emergence is rarely 
achieved. It involves available and effective intervention methods to interrupt transmission, 
preferably vaccines that elicit immunity in broad segments of society. Furthermore, easily 
available diagnostic tools and surveillance are required to detect possible cases before they can 
lead to transmission, and the reservoir for the virus must be limited to humans. Taking all of 
these factors into account, there are indications that even if the new SARS-CoV-2 disappears 
for a while, we might potentially see it coming back as an endemic cause of seasonal 
pneumonia. 
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Figure 1: Several factors influence how the SARS-CoV-2 outbreak will develop and end. 
A) Viral spread is fastest in immunologically naive population at the outbreak and eventually 
immunity limits transmission. The success of the vaccine against SARS-CoV-2, currently being 
in preparation for clinical phase one trial, might be a turning point. B) Viral evolution causes 
adaption to their host, and trade off high virulence for a better transmissibility and lower 
virulence. While it is early days to predict how exactly virulence will evolve in SARS-CoV-2, its 
evolution is ongoing and there are indications that SARS-CoV-2 has evolved into two strains 
since its emergence, the ancestral S-strain and a more “aggressive” L-strain [6].  C) Viruses 
survive much easier in a cold environment, as is reflected for example in the seasonality of 
influenza. D) Increased and effective public health efforts are the foundation of all strategies to 
limit spread of the virus and contribute to ending the outbreak. As the decreasing number of 
cases of SARS-CoV-2 in China depicts, rigid public health methods can be very successful in 
containing outbreaks. 
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